Fundamental Data for APPA

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company''s primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial targeted areas of application for the Company''s drug delivery technology include pain management, inflammation, oncology and ophthalmology applications.

# Employees: 18

Address: 123 Saginaw Drive,Redwood City,CA,USA

Phone: 650-366-2626

Fax: 650-365-6490

Website: www.appharma.com

Email: busdev@appharma.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Paul Goddard (Chmn.)

Gregory Turnbull (Presi.; C.E.O.; Interim C.F.O.; Princ. Acctg. Off.)

Toby Rosenblatt (Dir.)

Arthur Taylor (Dir.)

Peter Riepenhausen (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 4/6/2010

Mean EPS (Next Qtr): ($0.01)

Mean EPS (Year): ($0.01)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 0

Shares Performance

Period	APPA	Compare to S&P
YTD	117.86 %	80.30 %
4 Weeks	10.24 %	9.05 %
12 Weeks	7.65 %	1.49 %

Shares Information

Analyst Coverage: N

Avg Volume: 68801

Shares Outstanding: 31M

Market Cap: $0.03B

52 Week High: $1.07

52 Week Low: $0.40

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 5/25/2007 APPA split by factor of 0.250

Earnings Performance

EPS Growth in Last Quarter: 69.23 %

EPS Growth in Last Year: 80.00 %

Sales Growth in Last Quarter: 7,878.57 %

Sales Growth in Last Quarter: 1,645.31 %

Financials

Qtr Book Value: $59.81

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 24.770